TK2d

European Commission
#Clinical trial #European Commission #TK2d

EC grants marketing authorisation to rare disease drug 

The European Commission (EC) has granted marketing authorisation for Kygevvi (doxecitine and doxribtimine) for the treatment of thymidine kinase 2 deficiency (TK2d).  The approval, making Kygevvi the first and only treatment for TK2d, can now be used to treat paediatric and adult patients with the condition with… Read More

#News #Regulatory